SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors scrutinize the company's aggressive AI infrastructure spending and its impact on free cash flow despite strong ad revenue growth. The community is actively debating whether these heavy capital expenditures are a necessary strategic investment for long-term dominance or an unsustainable burden on margins that threatens shareholder value.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the broad UAE approval of Anktiva for bladder and lung cancer, sparking community optimism about the company's expanding global regulatory footprint. Investors are actively debating the timing of revenue growth and potential catalysts, while maintaining a cautious eye on upcoming earnings and significant short interest.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis is trending as investors weigh an aggressive turnaround strategy, including a 70 billion investment plan and a pivot back to core brands, against concerns over weak North American margins and inventory levels. Community discussion remains heavily polarized between bulls betting on a deep-value cyclical recovery and skeptics pointing to manufacturing challenges and intensifying global competition.

Arqit Quantum, Inc. engages in the provision of cybersecurity services via satellite and terrestrial forms. Its product is QuantumCloud which secures devices with cloud-based quantum encryption. The company was founded by David John Williams and David James Bestwick on April 26, 2021 and is headquartered in London, the United Kingdom.

Arqit Quantum Inc

Arqit Quantum is trending as investors speculate on a short squeeze fueled by an exceptionally low float, high institutional ownership, and significant short interest. The community is actively discussing the stock's potential for a parabolic reversal driven by its focus on post-quantum cryptography, recent government executive orders on quantum security, and key partnerships with major technology firms.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is experiencing intense community focus as investors track the upcoming U.S. commercial launch of the breast cancer therapy VEPPANU and monitor potential acquisition interest driven by the company's established commercial platform. While community sentiment remains divided over the impact of new market competition and the company's ability to maintain growth, discussions are heavily centered on the firm's evolving oncology pipeline and the belief that current valuation levels do not fully reflect its long-term commercial potential.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is facing significant downward pressure following a revenue miss in its latest earnings report, despite the company raising its full-year guidance and reaffirming strong demand for AI infrastructure. Community sentiment remains polarized, with many investors viewing the dip as a high-conviction buying opportunity supported by a massive backlog, while others express concern over the stock's premium valuation and susceptibility to broader AI-spending volatility.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is at the center of intense debate ahead of its earnings, with investors focused on whether strong AWS cloud revenue and AI demand can justify the massive capital expenditure fueling the company's data center expansion. The market remains volatile as traders weigh these long-term infrastructure investments against short-term margin pressures, making upcoming earnings guidance a critical catalyst for the stock's direction.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining momentum as investors weigh its strengthening commercial position against persistent speculation regarding its potential as an M&A target. The community is actively debating the stock's long-term value, focusing on recent research facility restructuring, high short interest levels, and institutional activity that signals a potential pivot toward a more aggressive growth or acquisition-led strategy.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as investors react to heightened geopolitical tensions in the Middle East and mixed earnings reports from major tech giants regarding AI-related capital expenditures. The community is actively debating the sustainability of the AI sector's rapid growth versus the potential for a broad market correction driven by interest rate concerns and shifting macroeconomic sentiment.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is facing significant downward pressure alongside the broader semiconductor sector as investors navigate concerns over AI capital expenditure cycles and global market volatility. While the community is deeply divided between those viewing the pullback as a long-term buying opportunity and those frustrated by recent price swings, sentiment remains heavily influenced by shifting macro conditions and sector-wide sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AMAT $LRCX Panicking out here, near 25xNTM,  is absolutely bonkers with the quality of mgmt, growth opportunity and consistency of performance the past 3 years…20% bounce recovery coming IMO off the qtr

StockTwits for iOS

Applied Materials Inc.

Lam Research Corp.

 Panicking out here, near 25xNTM,  is absolutely bonkers with the quality of mgmt, growth opportunity and consistency of performance the past 3 years…20% bounce recovery coming IMO off the qtr